S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
1970’s computer coder issues shocking A.I. warning (Ad)
What's Driving Tesla Lower Ahead of its Earnings?
3 Steel Stocks Could Soar on New China Tariffs
Did You Get Your Free Bitcoin Yet? (Ad)
How major US stock indexes fared Thursday, 4/18/2024
These are the Top 4 Stocks for Buybacks in 2024
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
1970’s computer coder issues shocking A.I. warning (Ad)
What's Driving Tesla Lower Ahead of its Earnings?
3 Steel Stocks Could Soar on New China Tariffs
Did You Get Your Free Bitcoin Yet? (Ad)
How major US stock indexes fared Thursday, 4/18/2024
These are the Top 4 Stocks for Buybacks in 2024
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
1970’s computer coder issues shocking A.I. warning (Ad)
What's Driving Tesla Lower Ahead of its Earnings?
3 Steel Stocks Could Soar on New China Tariffs
Did You Get Your Free Bitcoin Yet? (Ad)
How major US stock indexes fared Thursday, 4/18/2024
These are the Top 4 Stocks for Buybacks in 2024
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
1970’s computer coder issues shocking A.I. warning (Ad)
What's Driving Tesla Lower Ahead of its Earnings?
3 Steel Stocks Could Soar on New China Tariffs
Did You Get Your Free Bitcoin Yet? (Ad)
How major US stock indexes fared Thursday, 4/18/2024
These are the Top 4 Stocks for Buybacks in 2024
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
Free Trial
NASDAQ:VRPX

Virpax Pharmaceuticals (VRPX) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)
Free VRPX Stock Alerts
$4.04
+0.57 (+16.43%)
(As of 05:50 PM ET)
Compare
Today's Range
$3.34
▼
$4.04
50-Day Range
$2.70
▼
$4.95
52-Week Range
$2.40
▼
$11.77
Volume
20,060 shs
Average Volume
21,125 shs
Market Capitalization
$4.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media
VRPX stock logo

About Virpax Pharmaceuticals Stock (NASDAQ:VRPX)

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise PES200, which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.

VRPX Stock Price History

VRPX Stock News Headlines

April 13, 2024 | americanbankingnews.com
Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Short Interest Up 24.7% in March
April 2, 2024 | msn.com
Virpax Pharmaceuticals Set for Transformative Year with High Hopes for Non-Addictive Pain Management Solutions
April 18, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
March 26, 2024 | businesswire.com
Virpax Pharmaceuticals Reports 2023 Year-End Results
February 27, 2024 | finance.yahoo.com
Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price
February 27, 2024 | businesswire.com
Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price
February 27, 2024 | businesswire.com
Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.
February 12, 2024 | msn.com
Virpax Pharmaceuticals Reports Promising Results in Probudur Pilot Study
April 18, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
February 9, 2024 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Virpax Pharmaceuticals (VRPX) and I-MAB (IMAB)
February 7, 2024 | markets.businessinsider.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: Vertex Pharmaceuticals (VRTX) and EyePoint Pharmaceuticals (EYPT)
January 23, 2024 | investing.com
Virpax Pharmaceuticals Inc (VRPX)
December 29, 2023 | msn.com
Virpax Pharmaceuticals shareholders okay reverse stock split
December 28, 2023 | msn.com
Titan Pharmaceuticals to conduct 1-for-20 reverse stock split
November 22, 2023 | seekingalpha.com
VRPX Virpax Pharmaceuticals, Inc.
November 18, 2023 | markets.businessinsider.com
Promising Pipeline Developments and Market Opportunities Drive Buy Rating for Virpax Pharmaceuticals
November 17, 2023 | msn.com
Virpax Pharmaceuticals gets non-compliance notice from Nasdaq
November 17, 2023 | msn.com
Virpax Pharmaceuticals CEO and Chairman resigns on ongoing litigation
November 17, 2023 | finance.yahoo.com
Virpax Pharmaceuticals Announces Leadership Transition
November 17, 2023 | finance.yahoo.com
Virpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q Filing
November 15, 2023 | msn.com
Virpax Pharmaceuticals GAAP EPS of -$0.51
October 31, 2023 | finance.yahoo.com
Virpax Pharmaceuticals Announces that Envelta™ Remains on Track for Trial in Humans Following FDA Review
September 28, 2023 | markets.businessinsider.com
Analysts Are Bullish on These Healthcare Stocks: Virpax Pharmaceuticals (VRPX), Kura Oncology (KURA)
September 27, 2023 | finance.yahoo.com
Virpax Pharmaceuticals Announces Results of Probudur™ Dose Escalation Studies
September 26, 2023 | finance.yahoo.com
Virpax Pharmaceuticals to Present at the LD Micro Main Event XVI
September 21, 2023 | businesswire.com
Altasciences Chosen by Virpax to Support the Development of a New Drug to Prevent Spread of Flu-like Viruses
September 18, 2023 | finance.yahoo.com
Virpax Pharmaceuticals Announces the Formation of Novvae™ Pharmaceuticals
See More Headlines
Receive VRPX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Virpax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/18/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:VRPX
CUSIP
N/A
CIK
1708331
Web
www.virpaxpharma.com
Phone
610-727-4597
Fax
N/A
Employees
7
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($11.70)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-15,190,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-169.04%
Return on Assets
-106.39%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.25
Quick Ratio
1.25

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.65 per share
Price / Book
2.45

Miscellaneous

Outstanding Shares
1,170,000
Free Float
1,098,000
Market Cap
$4.73 million
Optionable
Not Optionable
Beta
1.38
10 Best Stocks to Own in 2024 Cover
10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Gerald W. Bruce (Age 67)
    CEO & Director
  • Dr. Jeffrey A. Gudin M.D. (Age 58)
    Executive VP, Chief Medical Officer & Director
    Comp: $204k
  • Mr. Vinay Shah A.C.A. (Age 62)
    M.B.A., CFO, Principal Financial Officer & Principal Accounting Officer
  • Dr. Sheila A. Mathias J.D.
    M.B.A., Ph.D., Chief Scientific Officer
  • Shana Panzarella
    Chief of Staff

Key Competitors

View All Competitors

VRPX Stock Analysis - Frequently Asked Questions

How have VRPX shares performed in 2024?

Virpax Pharmaceuticals' stock was trading at $3.2010 on January 1st, 2024. Since then, VRPX shares have increased by 26.2% and is now trading at $4.04.
View the best growth stocks for 2024 here.

Are investors shorting Virpax Pharmaceuticals?

Virpax Pharmaceuticals saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 29,800 shares, an increase of 24.7% from the March 15th total of 23,900 shares. Based on an average daily volume of 23,500 shares, the short-interest ratio is presently 1.3 days. Currently, 3.4% of the shares of the stock are short sold.
View Virpax Pharmaceuticals' Short Interest.

When is Virpax Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our VRPX earnings forecast.

When did Virpax Pharmaceuticals' stock split?

Shares of Virpax Pharmaceuticals reverse split on the morning of Friday, March 1st 2024. The 1-10 reverse split was announced on Friday, March 1st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Virpax Pharmaceuticals IPO?

Virpax Pharmaceuticals (VRPX) raised $15 million in an IPO on Wednesday, February 17th 2021. The company issued 1,400,000 shares at $10.00-$12.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO.

How do I buy shares of Virpax Pharmaceuticals?

Shares of VRPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VRPX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners
[Urgent!] Generational Wealth Gameplan
Crypto 101 Media
Biden’s $374B Giveaway Into This Sector
DTI
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press
Did You Get Your Free Bitcoin Yet?
Crypto Swap Profits
The Next Nvidia?
InvestorPlace
How Biden has already won 2024
Porter & Company
Options trading has suddenly become more reliable.
Eagle Publishing
1970’s computer coder issues shocking A.I. warning
TradeSmith